XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

Executive Summary

• XORTX Therapeutics Inc. has closed the acquisition of the VB4-P5 kidney anti-fibrotic asset from Vectus Biosystems Limited.
• The acquired program consists of a novel new chemical entity (VB4-P5) designed to inhibit and potentially reverse kidney fibrosis in both rare and prevalent forms of chronic kidney disease (CKD).
• The total acquisition price is US$3.0 million, settled via the issuance of common shares and pre-funded warrants.

Key Details

• Asset Acquired: VB4-P5 Renal Anti-Fibrotic Therapeutic Program, including:
  • Novel new chemical entity (VB4-P5).
  • Associated intellectual property (composition-of-matter and method-of-use claims across 30+ global jurisdictions).
  • Regulatory documentation and manufacturing data.
• Development Stage: Pre-IND (Investigational New Drug).
• Target Indications: Mid-late stage chronic kidney disease, autosomal dominant polycystic kidney disease (ADPKD), and lupus nephritis.
• Transaction Consideration: Total aggregate price of US$3.0 million, comprised of:
  • Common Shares: 154,544 shares at a deemed issue price of US$3.5432 (CAD$4.9668).
  • Pre-funded Warrants: 692,150 warrants at a deemed issue price of US$3.5431 (CAD$4.9667).
• Warrant Terms:
  • Exercise Price: US$0.0001.
  • Expiration Date: April 13, 2031.
  • Ownership Cap: Vectus is prohibited from exercising warrants if the result would lead to ownership exceeding 9.99% of XORTX's issued and outstanding common shares.
• Market Context: The company estimates the addressable market for this treatment exceeds 10 million individuals, noting that CKD affects approximately 14% of adults globally.

Notable Quotes

• Dr. Allen Davidoff, CEO of XORTX: “We are pleased to have finalized the Acquisition of the VB4-P5 program for kidney disease. This program is directly aligned with our strategic focus on developing innovative therapies to treat individuals with progressive kidney disease and broadens our pipeline with a new technological direction.”